XINGANJIANG
873167
Sichuan Goldstone
300434
Hangzhou Huasu Technology
301157
Xinjiang Tianshan Animal Husbandry Bio-engineering
300313
Suzhou Harmontronics Automation Technology
688022
CN Stock MarketDetailed Quotes
300006 Chongqing Lummy Pharmaceutical
- 3.63
- +0.14+4.01%
Trading Jan 6 10:29 CST
3.83BMarket Cap201.67P/E (TTM)
3.63High3.41Low225.06KlotVolume3.50Open3.49Pre Close79.69MTurnover2.13%Turnover RatioLossP/E (Static)1.06BShares6.4352wk High1.86P/B3.83BFloat Cap2.0352wk Low4.19Limit Up1.06BShs Float21.82Historical High2.79Limit Down6.30%Amplitude2.03Historical Low--Dividend TTM3.54Avg Price98.13KlotAsk--Div YieldTTM100Lot Size122.58KlotBid
Chongqing Lummy Pharmaceutical News
Laimei Pharmaceutical: Announcement on the results of the first instance judgment on the wholly-owned subsidiary lawsuit
Laimei Pharmaceutical: Announcement on participating in the tenth batch of national centralized drug procurement to be selected
Laimei Pharmaceutical: Legal Opinion of Beijing Zhonglun Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Chongqing Laimei Pharmaceutical Co., Ltd.
Laimei Pharmaceutical: Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Laimei Pharmaceutical: Announcement on the inclusion of the company\'s products in the medical insurance catalogue
Laimei Pharmaceutical: Proposed changes in the controlling shareholder and actual controller of the company
Laimei Pharmaceuticals: Notice on Obtaining Approval Notice for Drug Supplemental Applications
Laimei Pharmaceutical: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Laimei Pharmaceutical: Legal Opinion of Beijing Zhonglun Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Chongqing Laimei Pharmaceutical Co., Ltd.
Laimei Pharmaceutical: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Laimei Pharmaceuticals: Notice on Obtaining Approval Notice for Drug Supplemental Applications
Laimei Pharmaceutical: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024
Laimei Pharmaceuticals: Announcement on preparing for asset impairment in the first three quarters of 2024
Laimei Pharmaceuticals: Notice on Obtaining Approval Notice for Drug Supplemental Applications
Laimei Pharmaceutical: Announcement on the holding subsidiary obtaining ethical approval for phase II clinical trials of nano-carbon iron suspension injections
Chongqing Lummy Pharmaceutical: 《Regulations on Outbound Investment》(August 2024)
Chongqing Lummy Pharmaceutical: Announcement regarding the first-instance judgment result of the litigation involving a subsidiary under holding
Chongqing Lummy Pharmaceutical: Summary Table of Non-Operating Funds Used and Other Related Fund Transactions for the First Half of 2024.
Chongqing Lummy Pharmaceutical: Announcement on the Final Judgment of the Second Instance of the Lawsuit Matters Concerning the Company and Its Subsidiaries
Chongqing Lummy Pharmaceutical: Announcement about the retrial judgment result of the wholly-owned subsidiary's lawsuit.
